Rivaroxaban product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:59
Rivaroxaban product-specific bioequivalence guidance
Sitagliptin product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:56
Sitagliptin product-specific bioequivalence guidance
Tacrolimus granules product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 30 July 2025 - 9:51
Tacrolimus granules product-specific bioequivalence guidance
PSUSA/00000375/202410
Submitted by Anonymous (not verified) on 29 July 2025 - 15:45
PSUSA/00000375/202410
PSUSA/00001911/202412
Submitted by Anonymous (not verified) on 29 July 2025 - 15:44
PSUSA/00001911/202412
Fingolimod product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 29 July 2025 - 15:43
Fingolimod product-specific bioequivalence guidance
Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 29 July 2025 - 15:43
Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance
Entecavir product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 29 July 2025 - 15:40
Entecavir product-specific bioequivalence guidance
Record of data processing activity in the context of selection and recruitment procedures
Submitted by Anonymous (not verified) on 29 July 2025 - 12:37
Record of data processing activity in the context of selection and recruitment procedures
Summary of the Medicine Shortages SPOC Working Party meeting on 17 June 2025
Submitted by Anonymous (not verified) on 29 July 2025 - 8:47
Summary of the Medicine Shortages SPOC Working Party meeting on 17 June 2025